Victoza® is a once-daily injectable GLP-1 receptor agonist used to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It also reduces the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and established cardiovascular disease. Each Victoza® pen contains multiple doses and is designed for easy, flexible daily titration based on your healthcare provider’s recommendations.

Features:

• GLP-1 Receptor Agonist: Helps lower blood sugar by increasing insulin release, decreasing glucagon secretion, and slowing gastric emptying.

• Cardiovascular Risk Reduction: Clinically proven to lower the risk of major adverse cardiovascular events in adults with established heart disease.

• Adjustable Dosing: Delivers 0.6 mg, 1.2 mg, or 1.8 mg doses; titration guided by your healthcare provider.

• Prefilled Multi-Dose Pen: Each pen contains 18 mg of liraglutide (3 mL) and allows flexible dosing with a dial-a-dose mechanism.

• 2-Pack Convenience: Two pens provide up to 30 days of therapy, depending on dose.